1-4 of 4
Joseph Baar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Avia D. Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, Carley Mitchell, Paul G. Pavicic, Jr, Pingfu Fu, Amit Rupani, Hana Husic, Patricia A. Rayman, Shadi Swaidani, Jame Abraham, G. Thomas Budd, Halle Moore, Zahraa Al-Hilli, Jennifer S. Ko, Joseph Baar, Timothy A. Chan, Tyler Alban, C. Marcela Diaz-Montero, Alberto J. Montero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 82–93.
https://doi.org/10.1158/1078-0432.CCR-23-1349
Published: 05 January 2024
View articletitled, Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Open the PDF for Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

Joseph Baar, Paula Silverman, Janice Lyons, Pingfu Fu, Fadi Abdul-Karim, Nicholas Ziats, Jay Wasman, Paul Hartman, John Jesberger, Leda Dumadag, Erin Hohler, Rosemary Leeming, Robert Shenk, Helen Chen, Keith McCrae, Afshin Dowlati, Scot C. Remick, Beth Overmoyer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3583–3590.
https://doi.org/10.1158/1078-0432.CCR-08-2917
Published: 18 May 2009
View articletitled, A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
Open the PDF for A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers in another window
Journal Articles

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Kim Margolin, Michael B. Atkins, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith, II, Joseph I. Clark, Joseph Baar, Jeffrey Sosman, Jeffrey Weber, Chetan Lathia, Janice Brunetti, Frank Cihon, Brian Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3312–3319.
https://doi.org/10.1158/1078-0432.CCR-06-1341
Published: 01 June 2007
View articletitled, Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer
Open the PDF for Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer in another window
Journal Articles

Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma

Theresa L. Whiteside, Yongxiang Zhao, Takashi Tsukishiro, Elaine M. Elder, William Gooding, Joseph Baar
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 641–649.
Published: 01 February 2003
View articletitled, Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma
Open the PDF for Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma in another window